Table 3.
Progression-Free Survival and Overall Survival (response population).
| HGG (n = 19) | DIPG (n = 9) | Ependymoma (n = 9) | Medulloblastoma (n = 9) | |
|---|---|---|---|---|
| Progression-free survival per independent central review | ||||
| Events, n (%) | 17 (89.5) | 9 (100.0) | 9 (100.0) | 8 (88.9) |
| Time to event, median (95% CI), weeks a | 7.86 (5.14-8.14) | 11.29 (2.86-12.57) | 8.43 (5.57-16.14) | 8.43 (7.29-18.00) |
| Event-free rate, % (SE) | ||||
| Week 4 | 78.9 (9.35) | 88.9 (10.48) | 100.0 | 100.0 |
| Week 8 | 34.0 (11.20) | 66.7 (15.71) | 66.7 (15.71) | 66.7 (15.71) |
| Week 16 | 11.3 (7.54) | 0 | 33.3 (15.71) | 27.8 (16.17) |
| Week 24 | 11.3 (7.54) | ─ | 11.1 (10.48) | 0 |
| Week 32 | 5.7 (5.50) | ─ | 0 | ─ |
| Overall survival | ||||
| Events, n (%) | 12 (63.2) | 7 (77.8) | 5 (55.6) | 4 (44.4) |
| Time to event, median (95% CI), months a | 5.06 (2.04-11.63) | 3.78 (0.66-NA) | 12.02 (2.86-NA) | 11.60 (1.74-NA) |
| Event-free rate, % (SE) | ||||
| Month 3 | 65.7 (11.50) | 55.6 (16.56) | 88.9 (10.48) | 88.9 (10.48) |
| Month 6 | 44.3 (12.81) | 33.3 (15.71) | 59.3 (18.48) | 63.5 (16.92) |
| Month 9 | 35.5 (12.96) | 22.2 (13.86) | 59.3 (18.48) | 63.5 (16.92) |
| Month 12 | 11.8 (10.58) | 22.2 (13.86) | 59.3 (18.48) | 42.3 (20.64) |
DIPG, diffuse intrinsic pontine glioma; HGG, high-grade glioma; NA, not available; SE, standard error.
a
Median time to event based on Kaplan-Meier product-limit estimates.